MAPT and Alzheimer disease: We found a significant increase in the concentration of p‐tau181 (a marker of tauopathy) in the CSF of both AD‐tau/sham and AD‐tau/Aβ macaques, with a more robust effect size in the animals co‐injected with oligomeric Aβ (Figure 2A; Mann‐Whitney test: pooled‐CTL vs. AD‐tau/sham, p = 0.041; pooled‐CTL vs. AD‐tau/Aβ, p = 0.014).